Changing the game for periprosthetic joint infection.
For patients who face infection after joint replacement surgery, there is a new way forward.
At ForCast, we are pioneering the treatment of periprosthetic joint infection (PJI) with a targeted antibiotic therapy. Our mission is to modernize the standard of care for PJI and improve the quality of life for the growing population of joint replacement patients.
News & Press Releases
Denver, CO – August 5, 2025 – ForCast Orthopedics today announced the initial closing of a Series A equity financing round to support the development of its novel therapies for periprosthetic joint infection (PJI). The financing was led by OrthoInnovations, LLC, and its Managing Partner, Charles A. DeCook, MD, a renowned serial entrepreneur and leading orthopedic surgeon.
Read More
Contact
To learn more about ForCast: info@forcastortho.com
